Axonics (NSDQ:AXNX) announced today that it closed a public offering of common stock worth proceeds of more than $200 million. Irvine, Calif.-based Axonics, which develops the Axonics r-SNM (sacral neuromodulation) system to treat bladder and bowel dysfunction, offered more than 4 million shares of its common stock at $50 per share, according to a news […]
Axonics Modulation Technologies
Axonics announces $150M offering
Axonics (NSDQ:AXNX) announced today that it commenced a proposed public offering of common stock worth $150 million. Irvine, Calif.-based Axonics, which develops the Axonics r-SNM (sacral neuromodulation) system to treat bladder and bowel dysfunction, also expects to grant underwriters a 30-day option to purchase up to $22.5 million in additional shares of its common stock, […]
Axonics rises on mixed-bag Q1 results
Axonics (NSDQ:AXNX) posted first-quarter results that beat the revenue consensus on Wall Street but missed on earnings projections. The Irvine, Calif.-based company yesterday evening reported losses of –$22.5 million, or –57¢ per share, on sales of $34.4 million for the three months ended March 31 — versus a loss of –$14.6 million, or –43¢ per […]
Axonics, Micro Systems Technologies partners to make rechargeable SNM device
Axonics (NSDQ:AXNX) announced today that it entered into a strategic alliance with Micro Systems Technologies. Micro Systems Technologies (MST) manufactures printed circuit board assemblies for the Axonics r-SNM (sacral neuromodulation) system in Lake Oswego, Oregon, according to a news release. The newly minted strategic alliance expands the relationship between the two as the companies collaborate […]
Axonics acquires Contura and its Bulkamid bulking agent for $235M
Axonics (NSDQ: AXNX) announced today that it acquired Contura and its flagship Bulkamid product for up to $235 million. London-based Contura’s Bulkamid is a urethral bulking agent for women with stress urinary incontinence (SUI). It is a next-generation hydrogel injected into the urethral wall in a minimally invasive office or outpatient facility procedure to restore the natural […]
Axonics implantable neurostimulator wins FDA PMA supplemental approval
Axonics (NSDQ: AXNX) today said it received FDA PMA supplemental approval for its third-generation implantable neurostimulator. The new iteration go the device upgrades the embedded software in the implantable neurostimulator (INS), as well as the functionality of the patient remote control. The modifications give patients the ability to make broader stimulation parameter adjustments from home. It also […]
Axonics beats sales estimates in Q3
Axonics (NSDQ: AXNX) saw its stock tick up by 5.47% at the close of trading on third-quarter results that beat the consensus earnings forecast. The Irvine, Calif.-based sacral neuromodulation technologies company had a -$9.2 million loss, or -$0.24 per share, in the quarter ended September 30, 2020. The consensus estimate for the stock was a loss of […]
Axonics launches SNS postmarket study
Axonics Modulation Technologies (NSDQ:AXNX) announced today that it is launching a post-market clinical registry study for its r-SNM system. Irvine, Calif.-based Axonics’ implantable sacral neuromodulation (SNM) system is designed for treating urinary and bowel dysfunction with a battery life of 15 years or more. The Axonics Sacral Neuromodulation System Registry (Artistry) study is a prospective, multicenter […]
U.S. Patent Office to move forward with claims in Medtronic-Axonics patent battle
The U.S. Patent and Trademark Office (USPTO) Patent Trial and Appeal Board is moving forward with claims from Axonics Modulation Technologies (NSDQ:AXNX) against Medtronic (NYSE:MDT). Axonics develops the r-SNM sacral neuromodulation system, which it touts as the first of its kind approved for sale in the U.S., Europe, Canada and Australia and the only SNM device approved […]
UK recommends Axonics SNM for overactive bladder
Axonics Modulation Technologies (NSDQ:AXNX) announced today that NICE suggested using its r-SNM system in the UK. The National Institute for Health and Care Excellence (NICE) offers evidence-based guidance to the UK and, in guidance published last week, it recommended Axonics’ sacral neuromodulation (SNM) system for treating refractory overactive bladder for the country’s National Health Service (NHS). […]
Axonics beats on Q2 earnings despite losses
Axonics Modulation Technologies (NSDQ:AXNX) shares dipped slightly today on second-quarter results that beat the consensus earnings forecast. The Irvine, Calif.-based sacral neuromodulation (SNM) device maker posted losses of -$19.8 million, or -54¢ per share, on sales of $15.1 million for the three months ended June 30, 2020, for a -3.8% bottom-line slide on massive sales growth […]